Congenital Diaphragmatic Hernia

Congenital Diaphragmatic Hernia (CDH): Understanding a Life-Threatening Birth Defect

Congenital Diaphragmatic Hernia (CDH) is a serious developmental birth defect that occurs when the diaphragm — the thin muscle separating the chest from the abdomen — fails to form completely during early fetal development. This opening allows abdominal organs (such as the stomach, intestines, and often the liver) to herniate into the chest cavity, compressing the developing lungs and impairing their growth (pulmonary hypoplasia). In many cases, it also leads to persistent pulmonary hypertension of the newborn (PPHN), further complicating breathing and circulation after birth.

CDH is typically diagnosed prenatally via ultrasound (in ~85% of cases) or shortly after delivery through clinical signs and imaging.

Incidence and Scope

• Approximately 1 in 2,500 to 4,000 live births worldwide — This range aligns with long-standing estimates, but recent large-scale U.S. data shows a lower figure.
• Recent large-scale U.S. data indicating an incidence of about 1.3 per 10,000 live births — From a 2025 population-based study using CDC data (2016–2023), analyzing nearly 30 million live births, where 3,797 CDH cases were identified (1.3 per 10,000). Incidence showed no significant change over that period. Source: Shah ND et al., “Incidence and mortality trends in congenital diaphragmatic hernia in the United States,” Journal of Perinatal Medicine (2025). PubMed: 40967661.
• Left-sided CDH is most common (~85%) — This is a consistent finding across multiple registries and reviews (e.g., CDH Study Group data and standard epidemiology summaries).

Survival and Outcomes

• Overall survival to hospital discharge now ranges from 70–80% in experienced centers — Supported by multicenter reports and recent analyses.
  • A 2025 multicenter study from the Children’s Hospitals Neonatal Consortium (analyzing 3,639 infants) reported an unadjusted inpatient survival rate of 76.5%, with significant center-to-center variation (55.4% to 90.7%). Source: Guner YS et al., “Congenital diaphragmatic hernia outcomes: navigating center-to-center variability in level 4 NICUs,” Pediatric Research (2025).
  • High-volume centers often report 70–80% or higher for less severe cases, with improvements attributed to advances in care (gentle ventilation, ECMO protocols, multidisciplinary teams). Older estimates (~50–70%) have improved over decades.
• Survival varies widely based on factors such as defect severity, liver position, pulmonary hypoplasia, associated anomalies, and access to expert care — Confirmed in multiple sources, including the CDH Study Group registry and recent cohort studies (e.g., higher mortality with thoracic liver herniation, right-sided defects, or associated anomalies).
• Long-term challenges for survivors (chronic lung disease, GERD, neurodevelopmental issues, hearing loss, etc.) — Well-documented in follow-up guidelines and registry data, including the 2026 AAP clinical report on postdischarge follow-up for CDH infants.

Additional Notes on Progress

Advances in prenatal diagnosis (~80% via ultrasound), specialized neonatal strategies, and research (e.g., FETO for severe cases) have driven improvements — Reflected in declining infant mortality trends (e.g., CDH-related infant mortality rate dropped from 6.3 to 4.7 per 100,000 live births, 2007–2022, per CDC-linked data).

Key Facts at a Glance

• Incidence:
  • CDH affects approximately 1 in every 2,500 babies born.
    • Occurs early in pregnancy (weeks 4–10 of gestation).
• Cause: The exact cause is unknown in most cases, though research continues into genetic and environmental factors.
• Survival Rates: In higher-income countries with access to advanced neonatal care, survival to hospital discharge ranges from 50% to 80% (often higher in specialized centers). In lower- to middle-income countries, survival remains critically low, often less than 1%.
• Treatment and Impact:
  • Babies with CDH typically require urgent surgery to repair the diaphragm and may face extended hospital stays, intensive respiratory support, and potential long-term challenges.
  • There is no global Standard of Care for CDH, nor a national one in the United States, which makes insurance coverage problematic for some treatments.
  • Care for patients who reach adulthood and graduate out of pediatrics is one of the biggest hurdles survivors face
• Research Focus: lung regeneration, prenatal therapies, long-term outcomes